Tirzepatide vs semaglutide in coronary artery disease and obesity: Real-world cardiovascular outcomes analysis from the TriNetX research network

Authors

Ekow Essien, Advocate Health - MidwestFollow
Gloria Amoako
Abena Agyekum
Godslove Bonnah
Abraham Carboo
Karldon Nwaezeapu
Aba Kwakomah Dapaah

Recommended Citation

Essien E, Amoako G, Agyekum A, et al. Tirzepatide vs Semaglutide in Coronary Artery Disease and Obesity: Real-World Cardiovascular Outcomes Analysis from the TriNetX Research Network. American Heart Journal. 2025;290:26. doi:10.1016/j.ahj.2025.07.060

Type

Abstract